Comprehensive genomic analysis reveals clinically relevant molecular distinctions between thymic carcinomas and thymomas

Clinical Cancer Research

Volumn 15, Issue 22, 2009, Pages 6790-6799

  Girard, Nicolas ^a   Shen, Ronglai ^b   Guo, Tianhua ^b   Zakowski, Maureen F ^b   Heguy, Adriana ^b   Riely, Gregory J ^b   Huang, James ^b   Lau, Christopher ^a   Lash, Alex E ^b   Ladanyi, Marc ^a,b   Viale, Agnes ^b   Antonescu, Cristina R ^b   Travis, William D ^b   Rusch, Valerie W ^b   Kris, Mark G ^b,c   Pao, William ^a,b,c  

^a Human Oncology and Pathogenesis Program (HOPP)   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^c WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; IMATINIB; K RAS PROTEIN; STEM CELL FACTOR; SUNITIB MALATE; SUNITINIB; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CELL VIABILITY; CLINICAL ARTICLE; COMPARATIVE GENOMIC HYBRIDIZATION; FEMALE; GENE EXPRESSION; GENE MUTATION; GENETIC ANALYSIS; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG CARCINOMA; MALE; ONCOGENE H RAS; PRIORITY JOURNAL; THORAX TUMOR; THYMIC CARCINOMA; THYMOMA;

AGED; CARCINOMA; CLUSTER ANALYSIS; FEMALE; GENOMICS; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; MUTATION; NUCLEIC ACID HYBRIDIZATION; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROTO-ONCOGENE PROTEINS C-KIT; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION; THYMOMA; THYMUS NEOPLASMS;

EID: 72549108625     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-09-0644     Document Type: Article

References (50)

1. de Jong WK, Blaauwgeers JL, Schaapveld M, Timens W, Klinkenberg TJ, Groen HJ. Thymic epithelial tumours: a population-based study of the incidence, diagnostic procedures and therapy. Eur J Cancer 2008;44:123-130
2. Girard N, Mornex F, van Houtte P, Cordier JF, van Schil P. Thymoma: a focus on current therapeutic management. J Thorac Oncol 2008; 4:119-126
3. Eng TY, Fuller CD, Jagirdar J, Bains Y, Thomas CR. Thymic carcinoma: state of the art review. Int J Radiat Oncol Biol Phys 2004;59:654-664
4. WHO histological classification of tumours of the thymus. In: Travis WB, Brambilla A, Muller- Hermelinck HK, Harris CC, editors. World Health Organization classification of tumours. pathology and genetics of tumours of the lung, pleura, thymus and heart. Lyon: IARC Press; 2004, p. 146.
5. Masaoka A, Monden Y, Nakahara K, Tanioka T. Follow-up study of thymomas with special reference to their clinical stages. Cancer 1981;48: 2485-2492
6. Blumberg D, Port JL, Weksler B, et al. Thymoma: a multivariate analysis of factors predicting survival. Ann Thorac Surg 1995;60:908-913
7. Yoh K, Nishiwaki Y, Ishii G, et al. Mutational status of EGFR and KIT in thymoma and thymic carcinoma. Lung Cancer 2008;62:316-320
8. Tsuchida M, Umezu H, Hashimoto T, et al. Absence of gene mutations in KIT-positive thymic epithelial tumors. Lung Cancer 2008;62:321-325
9. Meister M, Schirmacher P, Dienemann H, et al. Mutational status of the epidermal growth factor receptor (EGFR) gene in thymomas and thymic carcinomas. Cancer Lett 2007;248:186-191
10. Suzuki E, Sasaki H, Kawano O, et al. Expression and mutation statuses of epidermal growth factor receptor in thymic epithelial tumors. Jpn J Clin Oncol 2006;36:351-356 (Pubitemid 44043923)
11. Pan CC, Chen PC, Chiang H. KIT (CD117) is frequently overexpressed in thymic carcinomas but is absent in thymomas. J Pathol 2004;202:375-381
12. Tateyama H, Eimoto T, Tada T, et al. p53 protein expression and p53 gene mutation in thymic epithelial tumors. An immunohistochemical and DNA sequencing study. Am J Clin Pathol 1995;104:375-381
13. Ströbel P, Hartmann M, Jakob A, et al. Thymic carcinoma with overexpression of mutated KIT and the response to imatinib. N Engl J Med 2004;350:2625-2626
14. Li XF, Chen Q, Huang WX, Ye YB. Response to sorafenib in cisplatin-resistant thymic carcinoma: a case report. Med Oncol 2009;26:157-160
15. Chuah C, Lim TH, Lim AS, et al. Dasatinib induces a response in malignant thymoma. J Clin Oncol 2006;24:e56-8.
16. Christodoulou C, Murray S, Dahabreh J, et al. Response of malignant thymoma to erlotinib. Ann Oncol 2008;19:1361-1362
17. Farina G, Garassino MC, Gambacorta M, La Verde N, Gherardi G, Scanni A. Response of thymoma to cetuximab. Lancet Oncol 2007;8:449-450
18. Zettl A, Ströbel P, Wagner K, et al. Recurrent genetic aberrations in thymoma and thymic carcinoma. Am J Pathol 2000;157:257-266
19. Chitale D, Gong Y, Taylor BS, et al. An integrated genomic analysis of lung cancer reveals loss of DUSP4in EGFR-mutant tumors. Oncogene 6;28:2773-2783
20. Ding L, Getz G, Wheeler DA, et al. Somatic mutations affect key pathways in lung adenocarcinoma. Nature 2008;455:1069-1075
21. Korn EL, McShane LM, Troendle JF, Rosenwald A, Simon R. Identifying pre-post chemotherapy differences in gene expression in breast tumours: a statistical method appropriate for this aim. Br J Cancer 2002;86:1093-1096 (Pubitemid 34438080)
22. Guo T, Agaram NP, Wong GC, et al. Sorafenib inhibits the imatinib-resistant KITT670I gatekeeper mutation in gastrointestinal stromal tumor. Clin Cancer Res 2007;13:4874-4881
23. Henley JD, Cummings OW, Loehrer PJ, Sr. Tyrosine kinase receptor expression in thymomas. J Cancer Res Clin Oncol 2004;130:222-224 (Pubitemid 38553631)
24. Nakagawa K, Matsuno Y, Kunitoh H,Maeshima A, Asamura H, Tsuchiya R. Immunohistochemical KIT (CD117) expression in thymic epithelial tumors. Chest 2005;128:140-144
25. Heinrich MC, Corless CL, Demetri GD, et al. Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol 2003;21:4342-4349 (Pubitemid 46621810)
26. Mol CD, Lim KB, Sridhar V, et al. Structure of a c-kit product complex reveals the basis for kinase transactivation. J Biol Chem 2003;278:31461-31464
27. Daley GQ, Baltimore D. Transformation of an interleukin 3-dependent hematopoietic cell line by the chronic myelogenous leukemia-specific P210bcr/abl protein. Proc Natl Acad Sci U S A 1988;85:9312-9316 (Pubitemid 19001887)
28. Heinrich MC, Maki RG, Corless CL, et al. Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor. J Clin Oncol 2008;26:5352-5359
29. Sasaki H, Ide N, Fukai I, Kiriyama M, Yamakawa Y, Fujii Y. Gene expression analysis of human thymoma correlates with tumor stage. Int J Cancer 2002;101:342-347
30. Penzel R, Hoegel J, Schmitz W, et al. Clusters of chromosomal imbalances in thymic epithelial tumours are associated with the WHO classification and the staging system according to Masaoka. Int J Cancer 2003;105:494-498
31. Lee GY, Yang WI, Jeung HC, et al. Genomewide genetic aberrations of thymoma using cDNA microarray based comparative genomic hybridization. BMC Genomics 2007;8:305.
32. Suzuki M, Chen H, Shigematsu H, et al. Aberrant methylation: common in thymic carcinomas, rare in thymomas. Oncol Rep 2005;14: 1621-1624
33. Kurup A, Burns M, Dropcho S, Pao W, Loehrer PJ. Phase II study of gefitinib treatment in advanced thymic malignancies. J Clin Oncol 2005;23:7068.
34. Pao W, Wang TY, Riely GJ, et al. KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib. PLoS Med 2005;2: e17.
35. Karapetis CS, Khambata-Ford S, Jonker DJ, et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 2008;359:1757-1765
36. Quinlan MP, Settleman J. Isoform-specific ras functions in development and cancer. Future Oncol 2009;5:105-116
37. Fasano O, Aldrich T, Tamanoi F, Taparowsky E, Furth M, Wigler M. Analysis of the transforming potential of the human H-ras gene by random mutagenesis. Proc Natl Acad Sci U S A 1984;81:4008-4012 (Pubitemid 14054513)
38. Qin B, Ariyama H, Baba E, et al. Activated Src and Ras induce gefitinib resistance by activation of signaling pathways downstream of epidermal growth factor receptor in human gallbladder adenocarcinoma cells. Cancer Chemother Pharmacol 2006;58:577-584
39. Inoue R, Matsuyama H, Yano S, Yamamoto Y, Iizuka N, Naito K. Gefitinib-related gene signature in bladder cancer cells identified by a cDNA microarray. Anticancer Res 2006;26:4195-4202 (Pubitemid 46031491)
40. Bedano PM, Perkins S, Burns M, et al. A phase II trial of erlotinib plus bevacizumab in patients with recurrent thymoma or thymic carcinoma. J Clin Oncol 2008;26:19087.
41. Giaccone G, Smit EF, van Groeningen C, Hogedoorn PC. Phase II study of imatinib in patients with WHO B3 and C thymomas. J Clin Oncol 2008;26:14665.
42. Bisagni G, Rossi G, Cavazza A, Sartori G, Gardini G, Boni C. Long lasting response to the multikinase inhibitor bay 43-9006 (Sorafenib) in a heavily pretreated metastatic thymic carcinoma. J Thorac Oncol 2009;4:773-775
43. Antonescu CR, Besmer P, Guo T, et al. Acquired resistance to imatinib in gastrointestinal stromal tumor occurs through secondary gene mutation. Clin Cancer Res 2005;11:4182-4190
44. Antonescu CR, Busam KJ, Francone TD, et al. L576P KIT mutation in anal melanomas correlates with KIT protein expression and is sensitive to specific kinase inhibition. Int J Cancer 2007;121:257-264
45. Salter JT, Lewis D, Yiannoutsos C, Loehrer PJ, Risley L, Chiorean EG. Imatinib for the treatment of thymic carcinoma. J Clin Oncol 2008;26:8116.
46. Carvajal RD, Chapman PB, Wolchok JD, et al. A phase II study of imatinib mesylate (IM) for patients with advanced melanoma harboring somatic alterations of KIT. J Clin Oncol 2009;27:9001.
47. Sasaki H, Ide N, Sendo F, et al. Glycosylphosphatidyl inositol-anchored protein (GPI-80) gene expression is correlated with human thymoma stage. Cancer Sci 2003;94:809-813
48. Fujita T, Kiyama M, Tomizawa Y, Kohno T, Yokota J. Comprehensive analysis of p53 gene mutation characteristics in lung carcinoma with special reference to histological subtypes. Int J Oncol 1999;15:927-934
49. Suster S, Moran CA. Thymoma, atypical thymoma, and thymic carcinoma. A novel conceptual approach to the classification of thymic epithelial neoplasms. Am J Clin Pathol 1999;111:826-833 (Pubitemid 29250114)
50. Marchevsky AM, Gupta R, McKenna RJ, et al. Evidence-based pathology and the pathologic evaluation of thymomas: the World Health Organization classification can be simplified into only 3 categories other than thymic carcinoma. Cancer 2008;112:2780-2788